Article
Phase IIb multicentred randomised trial of besifovir (LB80380) versus entecavir in Asian patients with chronic hepatitis B.
Gut - 1 Jun 2014
Lai Ching-Lung, Ahn Sang Hoon, Lee Kwan Sik, Um Soon Ho, Cho Mong, Yoon Seung Kew, Lee Jin-Woo, Park Neung Hwa, Kweon Young-Oh, Sohn Joo Hyun, Lee Jiyoon, Kim Jeong-Ae, Han Kwang-Hyub, Yuen Man-Fung
Abstract excerpt
BACKGROUND: Besifovir (LB80380) is an acyclic nucleotide phosphonate effective in hepatitis B virus (HBV) DNA suppression for both treatment-naive and lamivudine-resistant chronic hepatitis B (CHB) patients in preliminary studies. DESIGN: We aimed to compare the safety and antiviral activity of two doses of besifovir (90 mg and 150 mg daily) with entecavir 0.5 mg daily in CHB patients. 114 patients were...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.